Management of tuberculous meningitis in children

References

• Chiang SS, Khan FA, Milstein MB, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:947–957.
   Google Scholar
• van Toorn R, Schaaf HS, Laubscher JA, et al. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J. 2014;33:248–252.
   Google Scholar
• Wang M-S, Zhao M, Liu X-J. Risk factors for poor outcome in childhood tuberculous meningitis. Sci Rep. 2021;11:8654.
   Google Scholar
• Anjum N, Noureen N, Iqbal I. Clinical presentations and outcomes of the children with tuberculous meningitis: an experience at a tertiary care hospital. J Pak Med Assoc. 2018;68:10–15.
   Google Scholar
• Du Preez K, Schaaf HS, Dunbar R, et al. Incomplete registration and reporting of culture-confirmed childhood tuberculosis diagnosed in hospital. Public Health Action. 2011;1:19–24.
   Google Scholar
• Seddon JA, Tugume L, Solomons R, et al. The current global situation for tuberculous meningitis: epidemiology, diagnostics, treatment and outcomes. Wellcome Open Res. 2019;4:167.
   Google Scholar
• Ducomble T, Tolksdorf K, Karagiannis I, et al. The burden of extrapulmonary and meningitis tuberculosis: an investigation of national surveillance data, Germany, 2002 to 2009. Euro Surveill. 2013;18:20436.
   Google Scholar
• Schaaf HS, Garcia-Prats AJ, Draper HR, et al. Trends in drug resistance in childhood tuberculosis in Cape Town, South Africa. Pediatr Infect Dis J. 2020;39:604–608.
   Google Scholar
• Rich AR, McCordock HA. The pathogenesis of tuberculous meningitis. Bull Johns Hopkins Hosp. 1933;52:5–37.
   Google Scholar
• Donald PR, Schoeman JF. Tuberculous meningitis. N Engl J Med. 2004;351:1719–1720.
   Google Scholar
• Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol. 1993;22:1154–1158.
   Google Scholar
• Du Preez K, Seddon JA, Schaaf HS, et al. Global shortages of BCG vaccine and tuberculous meningitis in children. Lancet Glob Health. 2019;7:e28–e29.
   Google Scholar
• Huynh L, Agossah C, Lelong-Boulouard V, et al. Therapeutic drug monitoring of intravenous anti-tuberculous therapy: management of an 8-month-old child with tuberculous meningitis. Paediatr Int Child Health. 2021;41:1–6.
   Google Scholar
• Solomons R, Grantham M, Marais BJ, et al. IMCI indicators of childhood TBM at primary health care level in the Western Cape Province of South Africa. Int J Tuberc Lung Dis. 2016;20:1309–1313.
   Google Scholar
• Du Preez K, Hesseling AC, Mandalakas AM, et al. Opportunities for chemoprophylaxis in children with culture-confirmed tuberculosis. Ann Trop Paediatr. 2011;31:301–310.
   Google Scholar
• van den Bos F, Terken M, Ypma L, et al. Tuberculous meningitis and miliary tuberculosis in young children. Trop Med Int Health. 2004;9:309–313.
   Google Scholar
• Solomons RS, Visser DH, Friedrich SO, et al. Improved diagnosis of childhood tuberculous meningitis using more than one nucleic acid amplification test. Int J Tuberc Lung Dis. 2015;19:74–80.
   Google Scholar
• Andronikou S, Smith B, Hatherhill M, et al. Definitive neuroradiological diagnostic features of tuberculous meningitis in children. Pediatr Radiol. 2004;34:876–885.
   Google Scholar
• Bruwer GE, Van Der Westhuizen S, Lombard CJ, et al. Can CT predict the level of CSF block in tuberculous hydrocephalus? Childs Nerv Syst. 2004;20:183–187.
   Google Scholar
• Manyelo CM, Solomons RS, Snyders CI, et al. Potential of host serum protein biomarkers in the diagnosis of tuberculous meningitis in children. Front Pediatr. 2019;7:376.
   Google Scholar
• Wasserman S, Davis A, Wilkinson RJ, et al. Key considerations in the pharmacotherapy of tuberculous meningitis. Expert Opin Pharmacother. 2019;20:1791–1795.
   Google Scholar
• Davis A, Meintjes G, Wilkinson RJ. Treatment of tuberculous meningitis and its complications in adults. Curr Treat Options Neurol. 2018;20:5.
   Google Scholar
• Rajshekhar V. Management of hydrocephalus in patients with tuberculous meningitis. Neurol India. 2009;57:368–374.
   Google Scholar
• Donovan J, Rohlwink UK, Tucker EW, et al. Checklists to guide the supportive and critical care of tuberculous meningitis. Wellcome Open Res. 2019;4:163.
   Google Scholar
• Misra UK, Kalita J. Mechanism, spectrum, consequences and management of hyponatremia in tuberculous meningitis. Wellcome Open Res. 2019;4:189.
   Google Scholar
• Davis AG, Donovan J, Bremer M, et al. Host directed therapies for tuberculous meningitis. Wellcome Open Res. 2020;5:292.
   Google Scholar
• Solomons RS, Nieuwoudt ST, Seddon JA, et al. Risk factors for ischemic stroke in children with tuberculous meningitis. Childs Nerv Syst. 2021. DOI:https://doi.org/10.1007/s00381-021-05163-2.
   Google Scholar
• Padayatchi N, Bamber S, Dawood H, et al. Multidrug-resistant tuberculous meningitis in children in Durban, South Africa. Pediatr Infect Dis J. 2006;25:147–150.
   Google Scholar
• Panjasawatwong N, Wattanakul T, Hoglund RM, et al. Population pharmacokinetic properties of antituberculosis drugs in Vietnamese children with tuberculous meningitis. Antimicrob Agents Chemother. 2020;6. DOI:https://doi.org/10.1128/aac.00487-20.
   Google Scholar
• Savic RM, Ruslami R, Hibma JE, et al. Pediatric tuberculous meningitis: model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children. Clin Pharmacol Ther. 2015;98:622–629.
   Google Scholar
• Thwaites GE, Bhavnani SM, Chau TT, et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother. 2011;55:3244–3253.
   Google Scholar
• van Ewijk-Beneken Kolmer EWJ, Teulen MJA, van den Hombergh ECA, et al. Determination of protein-unbound, active rifampicin in serum by ultrafiltration and ultra performance liquid chromatography with UV detection. A method suitable for standard and high doses of rifampicin. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1063:42–49.
   Google Scholar
• Litjens CHC, Aarnoutse RE, Te Brake LHM. Preclinical models to optimize treatment of tuberculous meningitis – a systematic review. Tuberculosis (Edinb). 2020;122:101924.
   Google Scholar
• Akkerman OW, Odish OF, Bolhuis MS, et al. Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis. Clin Infect Dis. 2016;62:523–524.
   Google Scholar
• Pamreddy A, Baijnath S, Naicker T, et al. Bedaquiline has potential for targeting tuberculosis reservoirs in the central nervous system. RSC Adv. 2018;8:11902–11907.
   Google Scholar
• Tucker EW, Pieterse L, Zimmerman MD, et al. Delamanid central nervous system pharmacokinetics in tuberculous meningitis in rabbits and humans. Antimicrob Agents Chemother. 2019;63:e00913–e00919.
   Google Scholar
• Cresswell FV, Meya DB, Kagimu E, et al. High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly HIV-positive Ugandan adults: a phase II open-label randomised controlled trial. Clin Infect Dis. 2021. DOI:https://doi.org/10.1093/cid/ciab162.
   Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–1167.
   Google Scholar
• Lange C, Aarnoutse R, Chesov D, et al. Perspective for precision medicine for tuberculosis. Front Immunol. 2020;11:566608.
   Google Scholar
• Lange C, Dheda K, Chesov D, et al. Management of drug-resistant tuberculosis. Lancet. 2019;394:953–966.
   Google Scholar
• ClinicalTrials.gov. 2017. Optimizing treatment to improve TBM outcomes in children (TBM-KIDS). [cited 2018 Jun 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT02958709
   Google Scholar
• SURE: short intensive treatment for children with tuberculous meningitis. [cited 2019 May 25]. Available from: http://www.isrctn.com/ISRCTN40829906
   Google Scholar
• ClinicalTrials.gov. Linezolid, aspirin and enhanced dose rifampicin in HIV-TBM (LASER-TBM). [cited 2021 Jun 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT03927313
   Google Scholar
• ClinicalTrials.gov. Adjunctive linezolid for the treatment of tuberculous meningitis (ALTER). [cited 2021 Jun 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT04021121
   Google Scholar
• Garcia-Prats AJ, Purchase SE, Osman M, et al. Pharmacokinetics, safety, and dosing of novel pediatric levofloxacin dispersible tablets in children with multidrug-resistant tuberculosis exposure. Antimicrob Agents Chemother. 2019;63:e01865–18.
   Google Scholar
• Baijnath S, Naiker S, Shobo A, et al. Evidence for the presence of clofazimine and its distribution in the healthy mouse brain. J Mol Histol. 2015;46:439–442.
   Google Scholar
• Abulfathi AA, Donald PR, Adams K, et al. The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance. Br J Clin Pharmacol. 2020;86:2123–2132.
   Google Scholar